Neurocrine Biosciences PE ratio NBIX

Share price divided by earnings per share over the last twelve months, since 2012.

Today, Oct 23, 2026: 20.9×
8-year median: 42.8×
Against its 8-year history: 5th; percentile: 0 is its lowest day, 100 its highest
8-year range: 16.4× to 496×
Peer median: 37.6×

Neurocrine Biosciences' PE ratio is 20.9× as of Oct 23, 2026: a share price of $142.70 against $6.82 of earnings per share over the last twelve months.

That is below its 8-year median of 42.8×, lower than on 95% of days in the last 8 years.

Over that time it ranged from 16.4× in Jan 2022 to 496× in Feb 2019.

The median for 10 biotech stocks of a similar size is 37.6×.

PE ratio over time

median 42.8×

The dashed line is the 8-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	20.9×	19.9×	33.8×
2025	34.8×	27.6×	45.2×
2024	37.3×	31.4×	76.4×
2023	70.8×	57.6×	216×
2022	210×	16.4×	222×
2021	18.6×	17.4×	126×
2020	103×	44.8×	316×
2019	455×	452×	496×
2018	n/m a value too high to mean anything
2017	n/m a value too high to mean anything
2016	n/m a value too high to mean anything
2015	n/m a value too high to mean anything
2014	n/m a value too high to mean anything
2013	170×	155×	174×
2012	13.5×	10.7×	15.3×

Against its peers

Companies in Biotechnology nearest Neurocrine Biosciences' size, closest first, today.

Company	PE ratio
NBIXNeurocrine Biosciences	20.9×
HALOHalozyme Therapeutics	37.5×
EXELExelixis	20.3×
TECHBIO-TECHNE	63.1×
RGENRepligen	242×
KRYSKrystal Biotech	39.0×
INCYIncyte	14.7×
UTHRUnited Therapeutics	21.0×
ALNYAlnylam Pharmaceuticals	37.8×
ONCBeOne Medicines	67.6×
REGNRegeneron Pharmaceuticals	19.9×
Peer median	37.6×

Where Neurocrine Biosciences ranks

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Neurocrine Biosciences

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.